Sylver Quevedo's guest appearances

Sylver Quevedo

Mindrolling with Raghu Markus

Groundless Ground Podcast

OwlTail

Dr. Sylver Quevedo and Raghu jam on psychedelic preparation and integration, the MAPS MDMA studies, a Ram Dass ketamine story in India, and how 'love, serve, remember' connects to Indigenous wisdom.“One of the cardinal features that's been learned in the second psychedelic renaissance in the clinical trials has been the importance of two things that were not really understood that well in the 1960s—that is, preparation and integration. By contrast, one of the things that really was discovered early on and articulated very well by Ram Dass and Timothy Leary, was the importance of 'set and setting.' That has survived. It was figured out early on, never went away, and has been rediscovered over and over again.” – Dr. Sylver Quevedo Raghu and Sylver dive into:Taos, New Mexico; the Pueblo people; and the Neem Karoli Baba Ashram in Taos which houses the radiant and emotive Hanuman murti who jumped the ocean from India with Ram Dass and friends back in the day Working with MAPS (The Multidisciplinary Association for Psychedelic Studies) on their monumental MDMA for PTSD trials Psychedelics and love in the 1960s compared to psychedelics and science in the 2020s Ram Dass giving the "yogi medicine" LSD to his Guru, Neem Karoli Baba (Maharaj-ji) How Ram Dass and Maharaj-ji's lessons of "love, serve, remember" applies to Indigenous wisdom The transformational neural-plasticity and heart-opening properties of tryptamines and phenethylamines A fascinating Ram Dass on ketamine in India story, and Sylver's out-of-body revelation on ketamine"In the 1960s, we were mostly young and naive kids. But on the other hand, the ideals that came through there were real, even if we were misguided and naive about a lot of things like psychedelics. Now that science is part of the reality, in terms of the truth: the love and unity that we were pursing in the 1960s was a worthy cause." – Raghu MarkusAbout Dr. Sylver Quevedo:Dr. Sylver Quevedo is a psychedelic researcher who has practiced medicine for over 40 years and played major roles in world health projects. He is currently working with MAPS (The Multidisciplinary Association for Psychedelic Studies) on their monumental MDMA for PTSD trials. See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Dr. Sylver Quevedo and Raghu jam on psychedelic preparation and integration, the MAPS MDMA studies, a Ram Dass ketamine story in India, and how 'love, serve, remember' connects to Indigenous wisdom.“One of the cardinal features that's been learned in the second psychedelic renaissance in the clinical trials has been the importance of two things that were not really understood that well in the 1960s—that is, preparation and integration. By contrast, one of the things that really was discovered early on and articulated very well by Ram Dass and Timothy Leary, was the importance of 'set and setting.' That has survived. It was figured out early on, never went away, and has been rediscovered over and over again.” – Dr. Sylver Quevedo Raghu and Sylver dive into:<ul><li>Taos, New Mexico; the Pueblo people; and the <a href="https://nkbashram.org/" rel="noopener noreferrer nofollow" target="_blank">Neem Karoli Baba Ashram</a> in Taos which houses the radiant and emotive Hanuman murti who jumped the ocean from India with Ram Dass and friends back in the day</li><li> Working with <a href="https://maps.org/homepage/" rel="noopener noreferrer nofollow" target="_blank">MAPS (The Multidisciplinary Association for Psychedelic Studies)</a> on their monumental MDMA for PTSD trials</li><li> Psychedelics and love in the 1960s compared to psychedelics and science in the 2020s</li><li> Ram Dass giving the "yogi medicine" LSD to his Guru, Neem Karoli Baba (Maharaj-ji)</li><li> How Ram Dass and Maharaj-ji's lessons of "love, serve, remember" applies to Indigenous wisdom</li><li> The transformational neural-plasticity and heart-opening properties of tryptamines and phenethylamines</li><li> A fascinating Ram Dass on ketamine in India story, and Sylver's out-of-body revelation on ketamine</li></ul>"In the 1960s, we were mostly young and naive kids. But on the other hand, the ideals that came through there were real, even if we were misguided and naive about a lot of things like psychedelics. Now that science is part of the reality, in terms of the truth: the love and unity that we were pursing in the 1960s was a worthy cause." – Raghu MarkusAbout Dr. Sylver Quevedo:Dr. Sylver Quevedo is a psychedelic researcher who has practiced medicine for over 40 years and played major roles in world health projects. He is currently working with <a href="https://maps.org/homepage/" rel="noopener noreferrer nofollow" target="_blank">MAPS (The Multidisciplinary Association for Psychedelic Studies)</a> on their monumental MDMA for PTSD trials. See Privacy Policy at <a href="https://art19.com/privacy" rel="noopener noreferrer nofollow" target="_blank">https://art19.com/privacy</a> and California Privacy Notice at <a href="https://art19.com/privacy#do-not-sell-my-info" rel="noopener noreferrer nofollow" target="_blank">https://art19.com/privacy#do-not-sell-my-info</a>.

Ep. 497 - Psychedelic Preparation and Integration with Sylver Quevedo, MD, MPH

Psychedelic-assisted interventions appear to be all the rage these days. Though there are many psychedelic evangelists I wanted to find a credible medical resource to discuss these treatments. Deep gratitude to my friend Ron Purser who introduced me to my esteemed guest, Sylver Quevedo, MD, a pioneer in integrative family and internal medicine, assistant professor of medicine at Stanford and UCSF, co-Founder of Polaris Insight Center for Ketamine-assisted psychotherapy, and Principle Investigator in the FDA clinical trials on MDMA for Post-traumatic Stress Disorder. Our conversation was enlightening and it was fascinating to hear about Dr. Quevedo’s long history of work in public health, his devotion to providing medical care for indigenous populations in the American Southwest and Africa, and his enduring personal and professional interest in clinical use of psychedelic plant medicines. He beautifully explicates the biologic mechanisms of psilocybin, MDMA, ketamine, ayahuasca, mescaline and how these substances differ in effect and usefulness in psychotherapy. Dr. Quevedo is limited in discussing outcomes of the current phase 3 MDMA trials but he shared results of previous MDMA for PTSD trials, as well as use of psilocybin-assisted psychotherapy for end-of-life anxiety, depression, and ketamine-assisted psychotherapy for suicidal depression and chronic pain. So sit back and enjoy the journey this amazing physician takes us on.https://www.polarisinsight.com/https://maps.org Multidisciplinary Association for Psychedelic Studies https://clinicaltrials.gov/ NIH MDMA StudiesSylver Quevedo, MD, Internist Polaris Co-Founder and Medical Director has been in continuous practice of medicine for 40 years and practices nephrology, family, internal, and integrative medicine. He serves as Assistant Professor  at Stanford and UCSF.  He has played pivotal roles in several global health projects, including planning and development of medical and nursing school in Africa. The staff at Polaris Insight Center are dedicated to the ethical and compassionate clinical use of ketamine-assisted, and psychedelic-assisted, psychotherapy. Our founding members are all MAPS (Multi-disciplinary Association for Psychedelic Studies) trained clinicians who have participated in both Phase 2 and Phase 3 clinical trials of MDMA-assisted psychotherapy for PTSD.

Psychedelic-assisted interventions appear to be all the rage these days. Though there are many psychedelic evangelists I wanted to find a credible medical resource to discuss these treatments. Deep gratitude to my friend Ron Purser who introduced me to my esteemed guest, Sylver Quevedo, MD, a pioneer in integrative family and internal medicine, assistant professor of medicine at Stanford and UCSF, co-Founder of Polaris Insight Center for Ketamine-assisted psychotherapy, and Principle Investigator in the FDA clinical trials on MDMA for Post-traumatic Stress Disorder. Our conversation was enlightening and it was fascinating to hear about Dr. Quevedo’s long history of work in public health, his devotion to providing medical care for indigenous populations in the American Southwest and Africa, and his enduring personal and professional interest in clinical use of psychedelic plant medicines. He beautifully explicates the biologic mechanisms of psilocybin, MDMA, ketamine, ayahuasca, mescaline and how these substances differ in effect and usefulness in psychotherapy. Dr. Quevedo is limited in discussing outcomes of the current phase 3 MDMA trials but he shared results of previous MDMA for PTSD trials, as well as use of psilocybin-assisted psychotherapy for end-of-life anxiety, depression, and ketamine-assisted psychotherapy for suicidal depression and chronic pain. So sit back and enjoy the journey this amazing physician takes us on.<a href="https://www.polarisinsight.com/" rel="nofollow" target="_blank">https://www.polarisinsight.com/</a><a href="https://maps.org" rel="nofollow" target="_blank">https://maps.org</a> Multidisciplinary Association for Psychedelic Studies <a href="https://clinicaltrials.gov/" rel="nofollow" target="_blank">https://clinicaltrials.gov/</a> NIH MDMA StudiesSylver Quevedo, MD, Internist Polaris Co-Founder and Medical Director has been in continuous practice of medicine for 40 years and practices nephrology, family, internal, and integrative medicine. He serves as Assistant Professor  at Stanford and UCSF.  He has played pivotal roles in several global health projects, including planning and development of medical and nursing school in Africa. The staff at Polaris Insight Center are dedicated to the ethical and compassionate clinical use of ketamine-assisted, and psychedelic-assisted, psychotherapy. Our founding members are all MAPS (Multi-disciplinary Association for Psychedelic Studies) trained clinicians who have participated in both Phase 2 and Phase 3 clinical trials of MDMA-assisted psychotherapy for PTSD.